Results 31 to 40 of about 113,726 (260)
CEACAM1 participation in breast cancer progression
Molecular Oncology, EarlyView.In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin +3 more
wiley +1 more source
HORMONE REPLACEMENT THERAPY AND CANCER
Zdravniški Vestnik, 2003 Background. Sex steroids are not known to damage DNA directly. They can stimulate or inhibit cell proliferation, and thus can modulate tumor developmental progression.Results.
Marjetka Uršič Vrščaj
doaj
Brazilian Journal of OtorhinolaryngologyObjective: Compare the risk of developing Vestibular schwannoma in patients prescribed Hormone Therapy (HT). Methods: We performed a systematic review in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA), the
Maria Vitória Graça Couto de Campos Amaral +1 more
doaj +1 more source
Molecular Oncology, EarlyView.The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant +7 more
wiley +1 more source
OSTEOPOROSIS AND HORMONE REPLACEMENT THERAPY
Zdravniški Vestnik, 2008 BACKGROUND Osteoporosis affects almost every other woman after menopause. Fractures due to osteoporosis are a significant cause of disability and death, therefore we try to prevent themwith antiosteoporotic medications.Hormone replacement therapy (HRT ...
Tomaž Kocjan, Damir Franić
doaj
International Journal of Endocrinology, 2013 Objectives. Growth hormone deficiency patients exhibited reduced bone mineral density compared with healthy controls, but previous researches demonstrated uncertainty about the effect of growth hormone replacement therapy on bone in growth hormone ...
Peng Xue, Yan Wang, Jie Yang, Yukun Li
doaj +1 more source
Postmenopausal hormonal therapy: Current status
Indian Journal of Endocrinology and Metabolism, 2013 Many trials of the pros and cons of postmenopausal hormone replacement therapy have been done and this treatment has evolved over time. Here, we present a review and current status of this therapy.
V P Jyotsna
doaj +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon +11 more
wiley +1 more source
Endokrynologia PolskaHypoparathyroidism (HypoPT) remains the last “classic” endocrine deficiency hormone disorder not routinely treated with hormone replacement. In November 2023, European Medicines Agency (EMA), and in August 2024, Food and Drug Administration (FDA ...
Waldemar Misiorowski +6 more
doaj +1 more source